Sarilumab (IL-6R antagonist) in critically ill patients with cytokine release syndrome by SARS-CoV2

Blocking IL-6 pathways with sarilumab, a fully human anti–IL-6R antagonist may potentially curb the inflammatory storm of SARS-CoV2. In the present emergency scenario, we used “off-label” sarilumab in 5 elderly patients in life-threatening condition not candidates to further active measures. We sugg...

Descripción completa

Detalles Bibliográficos
Autores principales: Corominas, Hèctor, Castellví, Ivan, Diaz-Torné, César, Matas, Laia, de la Rosa, David, Mangues, Maria Antònia, Moya, Patricia, Pomar, Virginia, Benito, Natividad, Moga, Ester, Sosa, Nerea Hernandez-de, Casademont, Jordi, Domingo, Pere
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2021
Materias:
3600
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8133253/
https://www.ncbi.nlm.nih.gov/pubmed/34106658
http://dx.doi.org/10.1097/MD.0000000000025923
_version_ 1783695040400326656
author Corominas, Hèctor
Castellví, Ivan
Diaz-Torné, César
Matas, Laia
de la Rosa, David
Mangues, Maria Antònia
Moya, Patricia
Pomar, Virginia
Benito, Natividad
Moga, Ester
Sosa, Nerea Hernandez-de
Casademont, Jordi
Domingo, Pere
author_facet Corominas, Hèctor
Castellví, Ivan
Diaz-Torné, César
Matas, Laia
de la Rosa, David
Mangues, Maria Antònia
Moya, Patricia
Pomar, Virginia
Benito, Natividad
Moga, Ester
Sosa, Nerea Hernandez-de
Casademont, Jordi
Domingo, Pere
author_sort Corominas, Hèctor
collection PubMed
description Blocking IL-6 pathways with sarilumab, a fully human anti–IL-6R antagonist may potentially curb the inflammatory storm of SARS-CoV2. In the present emergency scenario, we used “off-label” sarilumab in 5 elderly patients in life-threatening condition not candidates to further active measures. We suggest that sarilumab can modulate severe COVID-19-associated Cytokine Release Syndrome.
format Online
Article
Text
id pubmed-8133253
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-81332532021-05-24 Sarilumab (IL-6R antagonist) in critically ill patients with cytokine release syndrome by SARS-CoV2 Corominas, Hèctor Castellví, Ivan Diaz-Torné, César Matas, Laia de la Rosa, David Mangues, Maria Antònia Moya, Patricia Pomar, Virginia Benito, Natividad Moga, Ester Sosa, Nerea Hernandez-de Casademont, Jordi Domingo, Pere Medicine (Baltimore) 3600 Blocking IL-6 pathways with sarilumab, a fully human anti–IL-6R antagonist may potentially curb the inflammatory storm of SARS-CoV2. In the present emergency scenario, we used “off-label” sarilumab in 5 elderly patients in life-threatening condition not candidates to further active measures. We suggest that sarilumab can modulate severe COVID-19-associated Cytokine Release Syndrome. Lippincott Williams & Wilkins 2021-05-14 /pmc/articles/PMC8133253/ /pubmed/34106658 http://dx.doi.org/10.1097/MD.0000000000025923 Text en Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC), where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc/4.0 (https://creativecommons.org/licenses/by-nc/4.0/) This article is made available via the PMC Open Access Subset for unrestricted re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the COVID-19 pandemic or until permissions are revoked in writing. Upon expiration of these permissions, PMC is granted a perpetual license to make this article available via PMC and Europe PMC, consistent with existing copyright protections.
spellingShingle 3600
Corominas, Hèctor
Castellví, Ivan
Diaz-Torné, César
Matas, Laia
de la Rosa, David
Mangues, Maria Antònia
Moya, Patricia
Pomar, Virginia
Benito, Natividad
Moga, Ester
Sosa, Nerea Hernandez-de
Casademont, Jordi
Domingo, Pere
Sarilumab (IL-6R antagonist) in critically ill patients with cytokine release syndrome by SARS-CoV2
title Sarilumab (IL-6R antagonist) in critically ill patients with cytokine release syndrome by SARS-CoV2
title_full Sarilumab (IL-6R antagonist) in critically ill patients with cytokine release syndrome by SARS-CoV2
title_fullStr Sarilumab (IL-6R antagonist) in critically ill patients with cytokine release syndrome by SARS-CoV2
title_full_unstemmed Sarilumab (IL-6R antagonist) in critically ill patients with cytokine release syndrome by SARS-CoV2
title_short Sarilumab (IL-6R antagonist) in critically ill patients with cytokine release syndrome by SARS-CoV2
title_sort sarilumab (il-6r antagonist) in critically ill patients with cytokine release syndrome by sars-cov2
topic 3600
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8133253/
https://www.ncbi.nlm.nih.gov/pubmed/34106658
http://dx.doi.org/10.1097/MD.0000000000025923
work_keys_str_mv AT corominashector sarilumabil6rantagonistincriticallyillpatientswithcytokinereleasesyndromebysarscov2
AT castellviivan sarilumabil6rantagonistincriticallyillpatientswithcytokinereleasesyndromebysarscov2
AT diaztornecesar sarilumabil6rantagonistincriticallyillpatientswithcytokinereleasesyndromebysarscov2
AT mataslaia sarilumabil6rantagonistincriticallyillpatientswithcytokinereleasesyndromebysarscov2
AT delarosadavid sarilumabil6rantagonistincriticallyillpatientswithcytokinereleasesyndromebysarscov2
AT manguesmariaantonia sarilumabil6rantagonistincriticallyillpatientswithcytokinereleasesyndromebysarscov2
AT moyapatricia sarilumabil6rantagonistincriticallyillpatientswithcytokinereleasesyndromebysarscov2
AT pomarvirginia sarilumabil6rantagonistincriticallyillpatientswithcytokinereleasesyndromebysarscov2
AT benitonatividad sarilumabil6rantagonistincriticallyillpatientswithcytokinereleasesyndromebysarscov2
AT mogaester sarilumabil6rantagonistincriticallyillpatientswithcytokinereleasesyndromebysarscov2
AT sosanereahernandezde sarilumabil6rantagonistincriticallyillpatientswithcytokinereleasesyndromebysarscov2
AT casademontjordi sarilumabil6rantagonistincriticallyillpatientswithcytokinereleasesyndromebysarscov2
AT domingopere sarilumabil6rantagonistincriticallyillpatientswithcytokinereleasesyndromebysarscov2

Ejemplares similares